Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health IEI testing Coverage & Policy Update …
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Diagnosis of Idiopathic Environmental Intolerance

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Oscar Health's coverage stance for diagnostic testing and evaluation related to idiopathic environmental intolerance (IEI)/multiple chemical sensitivity, including limits on laboratory and proprietary tests; applies to providers submitting claims for members covered by Oscar Health.

    Policy Summary
    PayerOscar Health
    PolicyDiagnosis of Idiopathic Environmental Intolerance
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionDo not order laboratory tests intended to confirm IEI; document clinical history, exam, basic labs, and rationale if specialized tests are requested.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    All IEI confirmation testsCategorical denial
    Does not meet criteriaBreath testing stance
    Examples citedProprietary panels
    1999Consensus year
    33.1%SIBO rate
    ~40+References

    Coverage Criteria for IEI / Multiple Chemical Sensitivity

    Tests and specimen analyses that do not meet criteria for IEI diagnosis

    Not covered — tests and situations that do not meet criteria

    Categorical exclusions: In all circumstances, laboratory tests designed to confirm the diagnosis of idiopathic environmental intolerance DO NOT MEET CRITERIA.

    Categorical denial applies regardless of setting.

    Asymptomatic/general encounter exclusions: For asymptomatic individuals and/or during general encounters without abnormal findings, the following DO NOT MEET CRITERIA: screening of blood, saliva, serum, plasma, urine, and/or stool samples for volatile solvents, organic acids, and organophosphates; profiling of phthalates and parabens using blood/serum/plasma/saliva/urine/stool; profiling of chlorinated pesticides (including DDE and DDT) using blood/serum/plasma/saliva/urine/stool; testing of blood/serum/plasma/saliva/urine/stool for carnitine sufficiency, oxidative stress/antioxidant sufficiency, detoxification adequacy, methylation sufficiency status, lipoic acid and CoQ10 sufficiency, and/or intestinal hyperpermeability; testing of blood/serum/plasma/saliva/urine/stool for vitamin, mineral, and/or nutritional analysis; metals testing of blood/serum/urine/cerebrospinal fluid/fingernails/hair/stool; and breath hydrogen and/or breath methane testing.

    List taken directly from policy exclusions (III. Indications and/or Limitations of Coverage).

    Covered when clinically indicated with appropriate pretest evaluation

    Coverage considerations for breath testing and related evaluations when clinically indicated:

    Symptom and evaluation prerequisites: Testing is most useful when patients have compatible symptoms (eg, bloating, abdominal pain, gas, diarrhea, constipation) and other diagnoses have been reasonably excluded by history, endoscopy, or imaging.

    Reflects guideline statements that breath testing is useful in symptomatic patients without alternative diagnoses.

    Test selection and intended use: Breath testing (glucose or lactulose hydrogen and/or methane) may be used to diagnose small intestinal bacterial overgrowth (SIBO) or carbohydrate maldigestion and to evaluate methane excretion when constipation is present; choice of substrate (glucose vs lactulose) affects sensitivity and specificity and may influence likelihood of response to antibiotic therapy.

    Reflects North American Expert Consensus and ACG recommendations (conditional/low–moderate evidence) and Rangan review findings on substrate differences.

    Consideration of predisposing factors and transit time: Interpretation should consider oro-cecal (orocecal) transit variability, prior gastrointestinal surgery, recent antibiotics, and other factors that can cause false-positive or false-negative results; breath testing should not be used to assess orocecal transit time per guideline cautions.

    Proprietary multi-analyte panels and broad micronutrient or toxicant panels are considered unnecessary for diagnosing idiopathic environmental intolerance (IEI) and do not meet coverage criteria when used for that purpose. Examples called out in the policy include Genova Diagnostics panels such as the Organix Comprehensive Profile, NutrEval, Food Sensitivity+, the GI Effects Profile, Ion Profile, Comprehensive Digestive Stool Analysis (CDSA) 2.0 and SIBO Profile; SpectraCell Laboratory tests including the Micronutrient Test and SPECTROX™; Life Extension nutrient panels; Vibrant Wellness nutrient panels; and Metabolomix+. These panels test many analytes (for example, up to 118 markers on some panels) but the policy states their routine use to diagnose IEI is not supported because IEI lacks reliable, testable characteristics.

    The policy explains that while some individual component tests within these panels (for example, stool culture, elastase, or tests for specific micronutrient deficiencies) may have legitimate indications in other clinical contexts, ordering these broad proprietary panels specifically to ‘‘confirm’’ or diagnose IEI is not appropriate and will not meet criteria.

    Major medical societies have expressed skepticism about IEI (formerly multiple chemical sensitivity) and advise against use of nonvalidated immune-based or otherwise unsupported laboratory tests to establish the diagnosis. The American Medical Association historically has stated IEI should not be recognized as a syndrome until accurate, reproducible, well-controlled studies exist, and the American College of Physicians and the American Academy of Allergy, Asthma & Immunology have expressed similar reservations.

    Specifically, the American Academy of Allergy, Asthma & Immunology (AAAAI) has noted that use of many nonvalidated immune-based tests to support an immunologic basis for IEI is expensive, not useful or valid, and should be discouraged — a position that supports excluding such tests when they are ordered to diagnose IEI.

    A targeted search identified no FDA-approved or -cleared diagnostic test for idiopathic environmental intolerance. The policy notes that many laboratories perform in-house assays that are laboratory-developed tests (LDTs); these LDTs are regulated under CLIA as high-complexity tests but are not approved or cleared by the U.S. Food and Drug Administration.

    Laboratory tests and proprietary panels intended to confirm IEI or to screen asymptomatic individuals without abnormal findings do not meet criteria. The policy lists multiple specimen-based screens (volatile solvents, organic acids, organophosphates), profiling of phthalates/parabens and chlorinated pesticides, vitamin/mineral/nutritional analyses, metals testing in various matrices, and breath hydrogen/methane testing among those that do not meet criteria when used to diagnose or screen for IEI.

    The policy emphasizes that because IEI lacks a reliable laboratory signature, ordering broad, non–evidence-based panels or using tests to ‘‘prove’’ IEI in asymptomatic or general encounters is not medically justified and may be denied.

    The policy identifies tests that lack standardization or validation as not supported for diagnosing IEI. This includes many carbohydrate breath tests and other breath testing approaches where preparation, performance, interpretation, and indications vary across centers, producing considerable heterogeneity and limited validation.

    Reviews cited in the policy note that for several carbohydrate breath tests (for example, fructose or sorbitol), no gold standard exists and validation studies are insufficient; even when breath tests are inexpensive and simple, the lack of standardization limits their accuracy and clinical utility for diagnosing IEI.

    Procedure and Billing Codes

    Listed CPT/HCPCS Procedure CodesCPT
    82108Aluminum.
    82127Amino acids; single, qualitative, each specimen.
    82136Amino acids, 2 to 5 amino acids, quantitative, each specimen.
    82139Amino acids, 6 or more amino acids, quantitative, each specimen.
    82300Cadmium.
    82379Carnitine (total and free), quantitative, each specimen.
    82380Carotene.
    82441Chlorinated hydrocarbons, screen.
    82495Chromium.
    82507Citrate.
    1–10 of 18
    1/2
    Applicable CPT/HCPCS Procedure CodesCPT
    82108Aluminum.
    82127Amino acids; single, qualitative, each specimen.
    82136Amino acids, 2 to 5 amino acids, quantitative, each specimen.
    82139Amino acids, 6 or more amino acids, quantitative, each specimen.
    82300Cadmium.
    82379Carnitine (total and free), quantitative, each specimen.
    82380Carotene.
    82441Chlorinated hydrocarbons, screen.
    82495Chromium.
    82507Citrate.
    1–10 of 39
    1/4
    Other referenced proceduresmixed
    Breath hydrogen/methane test (unnumbered in list)Breath hydrogen or methane test (eg, for detection of lactase deficiency, fructose intolerance, bacterial overgrowth, or oro-cecal gastrointestinal transit).

    Provider Actions, Documentation, and Authorization

    Prior Authorization

    Coverage restriction — IEI diagnostic tests are not covered

    In all circumstances, laboratory tests designed to confirm the diagnosis of idiopathic environmental intolerance (IEI) do not meet criteria and are subject to denial when billed as diagnostic confirmation; a broad set of specimen‑based panels (volatile solvents, organic acids, phthalates/parabens, chlorinated pesticides including DDE/DDT, vitamin/mineral/nutritional analyses, metals testing, and breath hydrogen/methane) are explicitly listed as not meeting criteria.

    • Categorical exclusion applies regardless of setting.
    • Breath hydrogen and/or breath methane testing is listed as not meeting criteria.
    Billing Rule

    Document specific procedure codes when ordering tests

    Background and Scope

    Idiopathic environmental intolerance (IEI), previously referred to as multiple chemical sensitivity (MCS), is described as a subjective condition characterized by recurrent, nonspecific symptoms that patients attribute to low-level exposures to chemical, biological, or physical agents without consistent objective diagnostic findings. Symptoms reported in the policy are heterogeneous and can include manifestations such as anxiety, shortness of breath, chest pain, gastrointestinal complaints, and other nonspecific somatic symptoms.

    The policy notes psychiatric comorbidity is common among affected individuals, and that there is no reliable laboratory signature for IEI. Because clinical presentations are variable and objective testing is generally lacking, the document advises a clinical-first evaluation (history, physical exam, targeted basic labs and selected objective testing) and cautions against reliance on unvalidated or broad laboratory panels to establish the diagnosis.

    Key Definitions and Instruments

    IEI — definition and brief description
    TermIdiopathic environmental intolerance (IEI)
    DefinitionA subjective condition with recurrent, nonspecific symptoms attributed to low levels of chemical, biologic, or physical agents in the absence of consistent objective diagnostic findings or laboratory tests.
    Also known asMultiple chemical sensitivity (MCS)
    Clinical note (most actionable)Evaluation should begin with history, physical exam, basic labs (CBC, serum electrolytes, glucose, urinalysis) and occupational/environmental history before ordering specialized tests.
    Associated considerationsPsychiatric comorbidity is common; use screening tools (eg, PHQ-9) as clinically appropriate.
    EESI — Environmental Exposure and Sensitivity Intolerance questionnaire for initial screening

    Policy Revision History

    1999consensus_reference

    An international Consensus Document (1999) establishing recognition criteria for Multiple Chemical Sensitivity (MCS) is cited as the most widely used criteria for recognition of MCS/IEI.

    2026-06-16governance_review

    Policy last reviewed by governance (document shows 'Last review 2026-06-16').

    2026-10-01effective_dateLatest
    Policy Summary
    PayerOscar Health
    PolicyDiagnosis of Idiopathic Environmental Intolerance
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionDo not order laboratory tests intended to confirm IEI; document clinical history, exam, basic labs, and rationale if specialized tests are requested.
    SourceLink
    On This Page
    Coverage Criteria for IEI / Multiple Chemical SensitivityProcedure and Billing CodesProvider Actions, Documentation, and AuthorizationBackground and ScopeKey Definitions and InstrumentsPolicy Revision History

    Draws on Rangan review and North American Expert Consensus guidance about transit time limitations and predisposing conditions.

    The policy lists numerous CPT/HCPCS codes for laboratory assays and related procedures that may be ordered in IEI evaluations; providers should be aware these procedure codes are enumerated in the policy and include heavy metals, organic acids, amino acids, and other specialty assays.

    • Examples of listed codes: 82108, 82127, 82300, 82441, 82978 (see policy code list).
    • Breath hydrogen/methane testing and related procedure descriptors are included in the code table.
    Prior Authorization

    Prior authorization may apply for listed specialty tests

    Prior authorization may be required for many specialized laboratory and diagnostic tests listed for IEI evaluation; verify payer PA requirements before ordering to avoid claim denials.

    • Policy note: "Prior authorization may be required per payer policy for many specialized laboratory and diagnostic tests listed by CPT/HCPCS when used for diagnosing idiopathic environmental intolerance; verify PA requirements before ordering."
    Step Therapy

    Clinical evaluation and basic testing must precede specialized testing

    Perform a clinical‑first evaluation: obtain a focused history (including occupational/environmental exposures), physical exam, and basic laboratory testing (CBC, serum electrolytes and glucose, urinalysis) and use screening tools (eg, EESI, PHQ‑9) as clinically appropriate before ordering specialized or proprietary panels.

    • Use targeted testing guided by reported symptoms; psychiatric screening is recommended since psychiatric comorbidity is common.
    • Avoid ordering specialized IEI panels without completing basic clinical evaluation documented in the record.
    Note

    Link breath testing to antibiotic‑directed therapeutic intent

    Breath hydrogen/methane testing is described as useful when intended to identify antibiotic‑responsive microbial colonization (eg, SIBO) or to evaluate methane in patients with constipation; document clinical indication and how results would change management (eg, guide antibiotic therapy).

    • Policy: breath testing may be used to assess antibiotic‑responsive microbial colonization and to evaluate methane with constipation.
    • Document predisposing conditions (prior GI surgery, recent antibiotics, transit issues) that affect interpretation.
    Step Therapy

    Step therapy guidance — none provided

    No step therapy requirements are specified in this policy section.

    • The policy explicitly states that no step therapy guidance is provided in this section.
    Documentation Required

    Required documentation — history, exam, basic labs, screening tools

    When requesting coverage or authorization, submit complete clinical documentation: history of compatible symptoms, physical exam findings, occupational/environmental exposure history, pertinent basic labs (CBC, electrolytes, glucose, urinalysis), and use of screening tools (EESI, PHQ‑9) where relevant.

    • Include documentation of prior evaluation steps and why basic testing did not explain symptoms.
    • Occupational/environmental history should be recorded when relevant.
    Documentation Required

    Clinical justification and diagnostic workup required

    Provide clinical justification and supporting diagnostic workup when ordering specialized tests: document compatible symptoms (eg, bloating, abdominal pain, gas, diarrhea, constipation), absence of alternative diagnoses on endoscopy or imaging, and consideration of predisposing conditions (eg, prior surgery, motility disorders) that make the test appropriate.

    • Policy notes breath testing is useful only in symptomatic patients without another diagnosis on endoscopy or imaging.
    • Consider and document factors that influence test interpretation (orocecal transit variability, recent antibiotics).
    Billing Rule

    Document exact procedure codes and clinical rationale

    When ordering tests for IEI, document the specific CPT/HCPCS procedure codes used from the policy code list and include the clinical rationale for each test in the medical record or PA submission.

    • The policy provides a full list of applicable procedure codes; include the exact code(s) on orders and authorization requests.
    • Failure to document specific procedure codes and rationale may lead to administrative denial or recoupment.
    Denial Risk

    High denial risk — tests intended to confirm IEI

    Ordering laboratory tests intended to confirm IEI will not meet coverage criteria and is a categorical basis for denial; do not order tests solely to 'confirm' IEI without meeting policy prerequisites and documentation requirements.

    • Policy statement: "In all circumstances, laboratory tests designed to confirm the diagnosis of idiopathic environmental intolerance DO NOT MEET CRITERIA."
    Denial Risk

    Societal skepticism of IEI testing may prompt denials

    Major medical societies (AMA, ACP, AAAAI) have expressed skepticism about IEI/MCS and discourage nonvalidated immune‑based or proprietary tests; this societal position may be cited in payer denials of such testing.

    • Policy cites AMA 1992 statement and similar positions from other societies as rationale for discouraging nonvalidated tests.
    Denial Risk

    Regulatory status (no FDA‑cleared tests) increases scrutiny

    Because no FDA‑cleared or approved test for IEI was identified and many tests are laboratory‑developed tests (LDTs), these tests may receive increased payer scrutiny and potential denials absent strong clinical justification and validation.

    • Policy: "No specific U.S. Food and Drug Administration (FDA) approval or clearance of a test for idiopathic environmental intolerance was found."
    • Document why an LDT is necessary and provide validation/clinical rationale when possible.
    Denial Risk

    LDT regulatory context — CLIA‑regulated, not FDA‑cleared

    Tests performed as laboratory‑developed tests (LDTs) are regulated under CLIA as high‑complexity tests and are not FDA‑approved or cleared; payers may subject LDTs to additional coverage review and potential denial if validation or clinical utility is not demonstrated.

    • Policy: LDTs "are regulated by the Centers for Medicare and Medicaid (CMS) as high‑complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U.S. Food and Drug Administration."
    • If ordering an LDT, include documentation of the test's CLIA status and supporting validation/utility evidence where available.
    ToolEnvironmental Exposure and Sensitivity Intolerance (EESI) questionnaire
    PurposeUsed for initial screening of patients reporting symptoms attributed to environmental exposures.
    Usage guidance (most actionable)May be used as part of initial clinical evaluation alongside history and physical to guide further targeted testing; document results in the medical record.
    ContextReferenced as a recommended screening questionnaire in the policy's evaluation pathway for IEI.
    PHQ-9 — Patient Health Questionnaire-9 screening tool reference
    ToolPatient Health Questionnaire-9 (PHQ-9)
    PurposeScreening tool to identify psychiatric conditions (eg, depression) that are often comorbid with IEI.
    Usage guidance (most actionable)Use PHQ-9 during the initial evaluation of suspected IEI to document psychiatric comorbidity and inform management and test selection.
    ContextRecommended in policy as part of psychiatric history and screening for IEI patients.
    Consensus Document recognition criteria for MCS/IEI (1999) — criteria elements
    Source1999 international Consensus Document on Multiple Chemical Sensitivity (MCS)
    Recognition criteria — chronicityChronic condition.
    Recognition criteria — reproducibilityReproducible symptoms with repeated chemical exposure.
    Recognition criteria — low exposureLow exposure levels cause the syndrome to occur.
    Recognition criteria — removal response (most actionable)Symptoms subside with removal of offending agents.
    Recognition criteria — cross-reactivityResponses occur to chemically unrelated substances.
    LDT (laboratory-developed test) — definition and regulatory framing
    DefinitionLaboratory-developed test (LDT): a test developed and validated by an individual laboratory and performed in-house.
    Regulatory framingLDTs are regulated by CMS under CLIA as high-complexity tests and are not approved or cleared by the U.S. Food and Drug Administration.
    Coverage implication (most actionable)Because no FDA-cleared IEI tests were identified and many assays are LDTs, use of such tests may be subject to increased payer scrutiny and potential denial unless validated and justified in the clinical record.
    Clinical noteLabs performing LDTs must validate them in-house per CLIA requirements; FDA clearance is not currently required for clinical use.
    Laboratory-developed test (duplicate entry) — alternate wording and CMS/CLIA context
    Alternate definitionA laboratory test developed and validated by a single laboratory and regulated by CMS under CLIA as a high-complexity test.
    FDA/CLIA contextLDTs are not FDA-cleared or approved; CMS regulates them under CLIA '88 for high-complexity testing.
    Policy relevance (most actionable)Policy notes no FDA-approved tests for IEI were found; tests described are frequently LDTs and therefore lack FDA clearance, which may affect coverage decisions.
    Laboratory responsibilityIndividual laboratories are responsible for in-house validation of LDT performance and accuracy per CLIA requirements.

    Policy effective date recorded as 2026-10-01.